Efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells for autologous transplantation in Japanese patients with multiple myeloma
Authors:
- 19 May 2017
- journal article
- research article
- Published by Springer Nature in International Journal of Hematology
- Vol. 106 (4) , 562-572
Abstract
To evaluate the efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells (HSCs) for autologous transplantation in Japanese patients with multiple myeloma (MM). In a randomized study, patients received G-CSF (filgrastim, 400 µg/m2/day) for 4 days prior to the first dose of plerixafor. Starting on Day 4 evening and for up to 4 days, patients received either plerixafor (240 µg/kg/day) + G-CSF group (PG group) or G-CSF alone (G group). Daily apheresis started on Day 5 for up to 4 days, or until ≥6 × 106 CD34+ cells/kg were collected. A total of 7 patients were randomized in each treatment group. Five patients in PG group and no patients in G group achieved a collection of ≥6 × 106 CD34+ cells/kg in ≤2 days of apheresis [difference of 71.4% (90%CI 29–100%)]. These results were supported by the shorter median time to collect ≥6 × 106 CD34+ cells/kg (2 days in PG group; no patient in G group). The incidence of treatment emergent adverse events (TEAEs) was higher in PG group than in G group. Plerixafor was well tolerated, and effective for the mobilization/collection of peripheral HSCs for autologous transplantation in Japanese patients with MM.Keywords
Funding Information
- Sanofi K.K.
This publication has 14 references indexed in Scilit:
- Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF aloneBone Marrow Transplantation, 2013
- How I treat patients who mobilize hematopoietic stem cells poorlyBlood, 2011
- High-Dose Therapy and Autologous Blood Stem-Cell Transplantation Compared With Conventional Treatment in Myeloma Patients Aged 55 to 65 Years: Long-Term Results of a Randomized Control Trial From the Group Myelome-AutogreffeJournal of Clinical Oncology, 2005
- Leukocytosis and Mobilization of CD34+ Hematopoietic Progenitor Cells by AMD3100, a CXCR4 AntagonistSupportive Cancer Therapy, 2004
- Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabineLeukemia, 2004
- High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple MyelomaNew England Journal of Medicine, 2003
- A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphomaBone Marrow Transplantation, 2000
- Dependence of Human Stem Cell Engraftment and Repopulation of NOD/SCID Mice on CXCR4Science, 1999
- Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recoveryTransplantation and Cellular Therapy, 1998
- Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma.1996